Strategy analysis

2019 Biomedtracker / Datamonitor Healthcare Post-AAN Report

May 28, 2019

Key Potential Drug Launches in 2020

May 28, 2019

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis therapies.

May 20, 2019

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.

May 20, 2019

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.

May 20, 2019

Biosimilar Commercial Strategies and Tactics

The challenges faced by biosimilar developers are not unlike those confronting their branded counterparts. First, companies must develop high-quality biosimilars and obtain regulatory approval. Next, they must then navigate the vast array of commercial nuances that exist at the national level in order for their products to be used in the clinical setting.

May 14, 2019

Gene Therapy Pipeline and Portfolio Analysis

$3,000.00

Gene therapy has undergone transformative enhancements over the last 20 years, with improvements to technologies and advances in the pipeline that aim to invigorate the field in its second generation.

April 23, 2019

Psoriasis Pricing, Reimbursement, and Access

Launch of multiple IL inhibitors with impressive efficacy has significantly reduced unmet need in the disease, and also provided payers with leverage in price negotiations as they seek to control growing treatment cost.

March 28, 2019

Multiple Myeloma Pricing, Reimbursement, and Access

Highlights: The budget impact of multiple myeloma is set to increase While multiple myeloma represents a relatively small patient population in comparison to other cancers, payers are concerned about the rising spend on the indication. New biologic therapies are increasingly gaining label expansions in earlier treatment lines, and with life expectancies improving, patients are requiring […]

March 5, 2019

Access Trends in Emerging Markets

$3,000.00

This report provides an in-depth analysis of the market access climate in emerging pharmaceutical markets. Focusing in particular on the E7 countries (Brazil, Russia, India, China, Mexico, Indonesia, and Turkey), it charts recent developments, assesses their potential impact on market access, and pinpoints areas in which further change is anticipated.

February 20, 2019

Pediatric Epilepsy KOL Interview – US, West

A US expert in pediatric epilepsy provides insight into the approach to treating different forms of epilepsy. The key opinion leader (KOL) dives into the late-phase pipeline for epilepsy, as well as sharing insight into Epidiolex.

February 18, 2019

Epilepsy KOL Interview – US, West

A US key opinion leader (KOL) discusses the epilepsy treatment landscape, including new market entrant Epidiolex, and provides their perspective on late-phase pipeline anti-epileptic drugs such as Fintepla.

February 18, 2019

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – UK

This interview covers hepatocellular carcinoma (HCC) treatment trends in the UK. We discuss current options for first- and second-line treatment, as well as therapies that are currently in Phase III clinical trials.

February 6, 2019